(Health-NewsWire.Net, December 10, 2016 ) The report provides comprehensive information on the Interleukin 13 (IL13) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 13 (IL13) targeted therapeutics development and features dormant and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
For more information about this report at http://www.reportsweb.com/interleukin-13-il13-pipeline-review-h2-2016
Scope
- The report provides a snapshot of the global therapeutic landscape for Interleukin 13 (IL13) - The report reviews Interleukin 13 (IL13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Interleukin 13 (IL13) targeted therapeutics and enlists all their major and minor projects - The report assesses Interleukin 13 (IL13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Interleukin 13 (IL13) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001492664/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Interleukin 13 (IL13) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Interleukin 13 (IL13) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Companies profiles Celgene Corporation Cell Medica Limited F. Hoffmann-La Roche Ltd. GlaxoSmithKline Plc MedImmune, LLC Molecular Partners AG Neovacs SA Novartis AG Sanofi
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001492664/discount
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Assessment by Monotherapy/Combination Products, H2 2016 17 Number of Products by Stage and Mechanism of Action, H2 2016 18
List of Figures Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Top 10 Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Assessment by Monotherapy/Combination Products, H2 2016 17 Number of Products by Stage and Mechanism of Actions, H2 2016 18 Number of Products by Routes of Administration, H2 2016 19 Number of Products by Stage and Routes of Administration, H2 2016 19 Number of Products by Molecule Types, H2 2016 21 Number of Products by Stage and Molecule Type, H2 2016 21
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|